<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646411</url>
  </required_header>
  <id_info>
    <org_study_id>300831</org_study_id>
    <nct_id>NCT01646411</nct_id>
  </id_info>
  <brief_title>300 Antibody Diagnostic Test Kit</brief_title>
  <acronym>Antibody 300</acronym>
  <official_title>Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Plasma Source</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Plasma Services Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Plasma Source</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the development of a Point of Care IVD test kit for acute phase disease detection against
      a variety of bacterial and viral infections. Phase one includes 100 clinical diagnosed
      positive and 200 clinically &quot;normal&quot; serum and whole blood matched specimens for specificity
      and sensitivity determination for each marker. The positive samples must be IgM positive
      using any FDA cleared ELISA test kit. The negatives samples must be negative for IgM.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IgM greater than 1xcut off value</measure>
    <time_frame>Antibody value measured within seven days of specimen collection.</time_frame>
    <description>Elisa System positive results are greater than 1 times the cutoff. Negative less than 1x cutoff.
Prevalence of IGM in general mid-atlantic population is less than 10% of study population.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Bacterial Infections</condition>
  <condition>Acute Viral Infections</condition>
  <arm_group>
    <arm_group_label>assorted acute infection</arm_group_label>
    <description>300 patients diagnosed with assorted acute infection.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum collected in two 10ml sst and two 8ml edta venipuncture tubes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute infection between the age of 18 and 70. Sex and race are random.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current acute infection

          -  age 18-70

          -  male or female

          -  any race

          -  currently active symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery Flieshman, M.S immunology</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>The Plasma Source</name>
      <address>
        <city>Southampton</city>
        <state>Pennsylvania</state>
        <zip>18966</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytomegalovirus (CMV) IgM &amp;IgG</keyword>
  <keyword>Lyme</keyword>
  <keyword>Toxoplasma</keyword>
  <keyword>Rubella</keyword>
  <keyword>Rubeola IgM</keyword>
  <keyword>Rocky mountain Spotted Fever IgM</keyword>
  <keyword>Ebv IgM</keyword>
  <keyword>Herpes</keyword>
  <keyword>Babesia</keyword>
  <keyword>Measles</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Mumps</keyword>
  <keyword>Mycoplasma</keyword>
  <keyword>Legionella</keyword>
  <keyword>Giardia</keyword>
  <keyword>Syphilis</keyword>
  <keyword>Bordetella Pertussis</keyword>
  <keyword>H Pylori</keyword>
  <keyword>Antibody Titre</keyword>
  <keyword>Elevated IgG</keyword>
  <keyword>Abnormal IgM</keyword>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

